These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28341370)

  • 1. Management of smoldering myeloma: Recommendations of the Spanish Myeloma Group.
    Mateos MV; Bladé J; Lahuerta JJ; San-Miguel J
    Med Clin (Barc); 2017 Jun; 148(11):517-523. PubMed ID: 28341370
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.
    Muchtar E; Kumar SK; Magen H; Gertz MA
    Leuk Lymphoma; 2018 Feb; 59(2):288-299. PubMed ID: 28592156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is aggressive treatment of smoldering myeloma the path to curing myeloma?
    Chakraborty R; Al Hadidi S; Cliff ERS; Mohyuddin GR
    Blood Adv; 2023 Aug; 7(15):3932-3935. PubMed ID: 37196639
    [No Abstract]   [Full Text] [Related]  

  • 4. The difficult business of assessing new therapies for smouldering multiple myeloma.
    Zonder JA
    Br J Haematol; 2018 Aug; 182(4):463-464. PubMed ID: 29767407
    [No Abstract]   [Full Text] [Related]  

  • 5. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management.
    Maciocia N; Wechalekar A; Yong K
    Hematol Oncol; 2017 Dec; 35(4):432-439. PubMed ID: 27804161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies.
    Visram A; Cook J; Warsame R
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):673-681. PubMed ID: 34889380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Controversies in the Management of Smoldering Multiple Myeloma.
    Lomas OC; Ghobrial IM
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-6. PubMed ID: 32223666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing treatment for smoldering myeloma: is earlier better?
    Hernández JÁ; Martínez-López J; Lahuerta JJ
    Expert Rev Hematol; 2019 May; 12(5):345-354. PubMed ID: 30907176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How I approach smoldering multiple myeloma.
    Vaxman I; Gertz MA
    Blood; 2022 Aug; 140(8):828-838. PubMed ID: 35576526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice.
    Cocito F; Mangiacavalli S; Ferretti VV; Cartia CS; Ganzetti M; Benveuti P; Pompa A; Catalano M; Fugazza E; Landini B; Arcaini L; Corso A
    Leuk Lymphoma; 2019 Dec; 60(12):2968-2974. PubMed ID: 31169049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smoldering multiple myeloma: biology, clinical manifestations and management.
    Nsiala L; Bobin A; Levy A; Gruchet C; Sabirou F; Gardeney H; Cailly L; Manier S; Moya N; Tomowiak C; Guidez S; Leleu X; Decaux O
    Leuk Lymphoma; 2022 Mar; 63(3):518-529. PubMed ID: 34672244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The consultant's guide to smoldering multiple myeloma.
    Thorsteinsdottir S; Kristinsson SY
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):551-559. PubMed ID: 36485144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pattern of the M-protein in smoldering myeloma over the time: an evolving risk factor.
    Fernández de Larrea C; Isola I; Pereira A; Cibeira MT; Bladé J; Rosiñol L
    Leukemia; 2018 Sep; 32(9):2082-2094. PubMed ID: 29795240
    [No Abstract]   [Full Text] [Related]  

  • 14. State of the science in smoldering myeloma: Should we be treating in the clinic?
    Hill E; Dew A; Kazandjian D
    Semin Oncol; 2019 Apr; 46(2):112-120. PubMed ID: 31072611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Early Intervention in High-Risk Smoldering Myeloma.
    Joseph NS; Dhodapkar MV; Lonial S
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-9. PubMed ID: 32182141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence.
    Musto P; La Rocca F
    Expert Rev Hematol; 2020 May; 13(5):501-517. PubMed ID: 32290723
    [No Abstract]   [Full Text] [Related]  

  • 17. Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma.
    Atrash S; Robinson M; Slaughter D; Aneralla A; Brown T; Robinson J; Ndiaye A; Sprouse C; Zhang Q; Symanowski JT; Friend R; Voorhees PM; Usmani SZ; Bhutani M
    Blood Cancer J; 2018 Nov; 8(11):107. PubMed ID: 30410066
    [No Abstract]   [Full Text] [Related]  

  • 18. Practical approach to the management of smoldering myeloma.
    Joseph NS; Lonial S
    Curr Opin Oncol; 2020 Nov; 32(6):656-663. PubMed ID: 32890022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Smoldering Multiple Myeloma: Expectant Observation Should Still Be the Standard.
    Fonseca R; Gonzalez-Velez M
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-7. PubMed ID: 32207672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'.
    Lakshman A; Ravi P; Rajkumar SV; Kumar SK
    Leukemia; 2018 Sep; 32(9):2083-2085. PubMed ID: 29802327
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.